{"id":67056,"date":"2026-06-02T13:08:17","date_gmt":"2026-06-02T05:08:17","guid":{"rendered":"https:\/\/flcube.com\/?p=67056"},"modified":"2026-06-02T13:08:18","modified_gmt":"2026-06-02T05:08:18","slug":"zelgen-biopharma-unveils-breakthrough-data-for-bispecific-and-trispecific-antibodies-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67056","title":{"rendered":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) presented compelling clinical data at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong> for two novel multispecific antibody programs: <strong>nilvanstomig (ZG005)<\/strong>, a PD-1\/TIGIT bispecific antibody, and <strong>alveltamig (ZG006)<\/strong>, a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.<\/p>\n\n\n\n<h2 id=\"h-nilvanstomig-zg005-phase-ii-hepatocellular-carcinoma-data\" class=\"wp-block-heading\">Nilvanstomig (ZG005) \u2013 Phase II Hepatocellular Carcinoma Data<\/h2>\n\n\n\n<h3 id=\"h-study-design-amp-key-results\" class=\"wp-block-heading\">Study Design &amp; Key Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>ZG005 20 mg\/kg + Bevacizumab<\/th><th>ZG005 10 mg\/kg + Bevacizumab<\/th><th>Sintilimab + Bevacizumab (Control)<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>First-line advanced HCC<\/td><td>First-line advanced HCC<\/td><td>First-line advanced HCC<\/td><\/tr><tr><td><strong>Progression-Free Survival<\/strong><\/td><td>HR=0.35 (95% CI: 0.15\u20130.76)<\/td><td>HR=0.41 (95% CI: 0.18\u20130.89)<\/td><td>Reference<\/td><\/tr><tr><td><strong>Risk Reduction<\/strong><\/td><td><strong>65% reduction<\/strong> in progression\/death<\/td><td><strong>59% reduction<\/strong> in progression\/death<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Statistical Significance<\/strong><\/td><td>Met primary endpoint<\/td><td>Met primary endpoint<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Well tolerated, favorable<\/td><td>Well tolerated, favorable<\/td><td>Consistent with known profiles<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>ZG005-005 Phase II trial<\/strong> demonstrated statistically significant improvements in progression-free survival for both nilvanstomig dose groups compared to the positive control arm, as assessed by independent review committee using RECIST v1.1 criteria.<\/p>\n\n\n\n<h2 id=\"h-alveltamig-zg006-trispecific-t-cell-engager-portfolio\" class=\"wp-block-heading\">Alveltamig (ZG006) \u2013 Trispecific T-Cell Engager Portfolio<\/h2>\n\n\n\n<h3 id=\"h-small-cell-lung-cancer-sclc-results\" class=\"wp-block-heading\">Small Cell Lung Cancer (SCLC) Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Dose<\/th><th>ORR<\/th><th>mPFS<\/th><th>mDoR<\/th><th>Safety<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I\/II (ZG006-001)<\/strong><\/td><td>Multiple doses<\/td><td>Robust activity<\/td><td><strong>9.6 months<\/strong><\/td><td><strong>9.7 months<\/strong><\/td><td>Acceptable<\/td><\/tr><tr><td><strong>Phase II Optimization (ZG006-002)<\/strong><\/td><td>10 mg<\/td><td><strong>53.3%<\/strong><\/td><td><strong>7.03 months<\/strong><\/td><td>Not specified<\/td><td>Well tolerated<\/td><\/tr><tr><td><strong>Phase II Optimization (ZG006-002)<\/strong><\/td><td>30 mg<\/td><td><strong>56.7%<\/strong><\/td><td><strong>5.59 months<\/strong><\/td><td>Not specified<\/td><td>Well tolerated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-neuroendocrine-carcinoma-results\" class=\"wp-block-heading\">Neuroendocrine Carcinoma Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Dose<\/th><th>Confirmed ORR<\/th><th>DCR<\/th><th>mPFS<\/th><th>Safety<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II Expansion (ZG006-003)<\/strong><\/td><td>10 mg Q2W<\/td><td><strong>33.3%<\/strong><\/td><td><strong>50.0%<\/strong><\/td><td><strong>3.02 months<\/strong><\/td><td>Acceptable<\/td><\/tr><tr><td><strong>Phase II Expansion (ZG006-003)<\/strong><\/td><td>30 mg Q2W<\/td><td><strong>56.3%<\/strong><\/td><td><strong>75.0%<\/strong><\/td><td><strong>7.06 months<\/strong><\/td><td>Acceptable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profiles-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profiles &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-nilvanstomig-zg005\" class=\"wp-block-heading\">Nilvanstomig (ZG005)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type:<\/strong> Recombinant humanized anti-PD-1\/TIGIT bispecific antibody (BsAb)<\/li>\n\n\n\n<li><strong>Targets:<\/strong> Dual immune checkpoint inhibition (PD-1 + TIGIT pathways)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Simultaneous blockade of complementary immune evasion mechanisms<\/li>\n\n\n\n<li><strong>Indication:<\/strong> First-line advanced hepatocellular carcinoma (HCC)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-alveltamig-zg006\" class=\"wp-block-heading\">Alveltamig (ZG006)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Type:<\/strong> Trispecific T-cell engager<\/li>\n\n\n\n<li><strong>Targets:<\/strong> CD3 (T-cell receptor) + two distinct DLL3 epitopes (tumor antigen)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Redirects T-cells to DLL3-expressing tumor cells with enhanced avidity<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Advanced small cell lung cancer (SCLC) and neuroendocrine carcinoma<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-implications\" class=\"wp-block-heading\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>HCC Market Opportunity<\/strong><\/td><td>Global HCC market projected to reach $8.5 billion by 2030; first-line segment represents largest addressable population<\/td><\/tr><tr><td><strong>SCLC Treatment Gap<\/strong><\/td><td>Limited effective therapies for refractory SCLC; median survival historically &lt;10 months<\/td><\/tr><tr><td><strong>Multispecific Antibody Trend<\/strong><\/td><td>Growing validation of bispecific\/trispecific platforms in oncology (e.g., Blincyto, Rybrevant)<\/td><\/tr><tr><td><strong>Chinese Innovation<\/strong><\/td><td>Zelgen joins elite group of Chinese biotechs presenting breakthrough data at major international conferences<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>ZG005&#8217;s dual checkpoint approach vs. monospecific PD-1 inhibitors; ZG006&#8217;s trispecific design vs. bispecific alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-amp-development-outlook\" class=\"wp-block-heading\">Financial &amp; Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Both programs positioned for accelerated approval discussions based on robust efficacy data<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong ASCO data likely to attract global pharma partnership interest<\/li>\n\n\n\n<li><strong>Market Valuation Impact:<\/strong> Positive data could significantly re-rate Zelgen&#8217;s market capitalization (currently ~$2.1 billion)<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success validates Zelgen&#8217;s multispecific antibody platform for additional pipeline candidates<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and clinical trial variability.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260602_YUQ9.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260602_YUQ9.\"><\/object><a id=\"wp-block-file--media-eb734183-b280-4ea7-9400-841e559be20d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260602_YUQ9.pdf\">688266_20260602_YUQ9<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688266_20260602_YUQ9.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-eb734183-b280-4ea7-9400-841e559be20d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,246],"class_list":["post-67056","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67056\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67056\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T05:08:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-02T05:08:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026\",\"datePublished\":\"2026-06-02T05:08:17+00:00\",\"dateModified\":\"2026-06-02T05:08:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056\"},\"wordCount\":504,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67056#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67056\",\"name\":\"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-02T05:08:17+00:00\",\"dateModified\":\"2026-06-02T05:08:18+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\\\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67056\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67056#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67056","og_locale":"en_US","og_type":"article","og_title":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.","og_url":"https:\/\/flcube.com\/?p=67056","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-02T05:08:17+00:00","article_modified_time":"2026-06-02T05:08:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67056#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67056"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026","datePublished":"2026-06-02T05:08:17+00:00","dateModified":"2026-06-02T05:08:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67056"},"wordCount":504,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Cancer","Clinical trial results","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67056#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67056","url":"https:\/\/flcube.com\/?p=67056","name":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-02T05:08:17+00:00","dateModified":"2026-06-02T05:08:18+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for two novel multispecific antibody programs: nilvanstomig (ZG005), a PD-1\/TIGIT bispecific antibody, and alveltamig (ZG006), a trispecific T-cell engager targeting CD3 and dual DLL3 epitopes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67056#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67056"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67056#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67056"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67056\/revisions"}],"predecessor-version":[{"id":67058,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67056\/revisions\/67058"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}